Is Jagsonpal Pharmaceuticals a good stock to invest in?

Jagsonpal Pharmaceuticals can be analyzed on the following key metrics - TTM P/E: 26.5 Sector P/E: 24.5 Dividend Yield: 1.17% D/E ratio: -

Jagsonpal Pharmaceuticals Share Price

Sector: Major Drugs

Powered by

217.15 +4.05 (1.90%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 212.95

Today’s High 217.95

52 Week Low 109.42

52 Week High 328.02

Key Metrics

Market Cap (In Cr) 1439.43
Beta 1.07
Div. Yield (%) 1.17
P/B 5.9
TTM P/E 26.5
Peg Ratio 0.62
Sector P/E 24.5
D/E 0
Open Price 215.15
Prev Close 213.1

View All Metrics

Jagsonpal Pharmaceuticals Analysis

Price Analysis

1 Week

4.3%
3 Months

-7.22%
6 Month

-0.11%
YTD

-12.76%
1 Year

57.2%

Risk Meter

70% Low risk
70% Moderate risk
70% Balanced Risk
70% High risk
70% Extreme risk

Jagsonpal Pharmaceuticals News

Companies reporting their results on 26 July include IndusInd Bank, Power Grid Corporation, Shriram Finance, Cipla, InterGlobe Aviation, Bandhan Bank, Aarti Drugs, Amber Enterprises India, Cholamandalam Investment and Finance, KEC International, KFin Technologies, Latent View Analytics, Nuvama Wealth Management, Piramal Pharma, SBI Cards and Payment Services, and TTK Prestige, among others. (Photo: Reuters)

Premium

Stocks to watch: Mankind, TechM, IndiGo, Adani Green, DLF, Ashok Leyland

9 min read . 26 Jul 2024

View More News

Jagsonpal Pharmaceuticals Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2025

Total Revenue
268.72

Selling/ General/ Admin Expenses Total
64.13

Depreciation/ Amortization
8.13

Other Operating Expenses Total
50.27

Total Operating Expense
206.09

Operating Income
62.63

Net Income Before Taxes
69.86

Net Income
55.36

Diluted Normalized EPS
5.9

Period
2024

Total Revenue
208.7

Selling/ General/ Admin Expenses Total
91.96

Depreciation/ Amortization
1.66

Total Operating Expense
187.24

Operating Income
21.46

Net Income Before Taxes
29.87

Net Income
22.46

Diluted Normalized EPS
3.39

Period
2023

Total Revenue
236.71

Selling/ General/ Admin Expenses Total
99.55

Depreciation/ Amortization
1.18

Total Operating Expense
206.54

Operating Income
30.17

Net Income Before Taxes
34.81

Net Income
26.72

Diluted Normalized EPS
4.45

Period
2022

Total Revenue
217.58

Selling/ General/ Admin Expenses Total
101.8

Depreciation/ Amortization
1.53

Total Operating Expense
193.08

Operating Income
24.5

Net Income Before Taxes
26.64

Net Income
18.86

Diluted Normalized EPS
2.87

Period
2021

Total Revenue
187.95

Selling/ General/ Admin Expenses Total
53.98

Depreciation/ Amortization
1.09

Other Operating Expenses Total
34.11

Total Operating Expense
169.95

Operating Income
17.99

Net Income Before Taxes
21.87

Net Income
17.06

Diluted Normalized EPS
2.6

Period
2020

Total Revenue
158.57

Selling/ General/ Admin Expenses Total
50.37

Depreciation/ Amortization
1.13

Other Operating Expenses Total
43.47

Total Operating Expense
151.17

Operating Income
7.4

Net Income Before Taxes
9.41

Net Income
7.87

Diluted Normalized EPS
1.2

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Jagsonpal Pharmaceuticals Technical

Moving Average SMA

5 Day218.57
10 Day221.63
20 Day225.93

50 Day219.14
100 Day228.83
300 Day210.64

Jagsonpal Pharmaceuticals Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Neuland Laboratories
11122.9
69.7
0.63
18089.55
5557
14270.56

Unichem Laboratories
606.3
13.75
2.32
949.85
507.2
4267.6

Jagsonpal Pharmaceuticals
217.15
4.05
1.9
328.02
109.42
1439.43

Themis Medicare
162.85
13.45
9
313.65
115.05
1504.89

Ind-swift Laboratories
73.49
2.19
3.07
186
67.15
447.83

Jagsonpal Pharmaceuticals Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

06-May-25
Audited Results & Final Dividend

22-Jan-25
Quarterly Results

23-Oct-24
Quarterly Results & Stock Split

07-Aug-24
Quarterly Results

20-May-24
Audited Results & Final Dividend

02-Feb-24
Quarterly Results

03-Nov-23
Quarterly Results

02-Aug-23
Quarterly Results

23-May-23
Audited Results & Dividend

08-Feb-23
Quarterly Results

Meeting Date
Announced on
Purpose

13-Dec-24
11-Nov-24
POM

18-Sept-24
07-Aug-24
AGM

31-Aug-23
02-Aug-23
AGM

14-Sept-22
09-Aug-22
AGM

17-Jun-22
20-May-22
EGM

Announced on
Record Date
Ex-Dividend
Dividend Value

06-May-25
-
-
2.5

21-May-24
06-Sept-24
06-Sept-24
5

23-May-23
21-Aug-23
21-Aug-23
5

19-Oct-21
01-Nov-21
29-Oct-21
4

30-Jun-21
-
22-Sept-21
1

Ex-Splits
Old FV
New FV
Description

08-Jan-25
5
2
Stock split from Rs. 5/- to Rs. 2/-.

View All

Company Profile

ABOUT Jagsonpal Pharmaceuticals

Industry Major Drugs
ISIN INE048B01035
BSE Code 507789
NSE Code JAGSNPHARM

Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yuliprist, Deereg, and Lycored Softgel. Its Orthopaedics products include JP Tone Up, Metadec 50 Injection, Metadec 25 Injection, Indocap SR, and Indocap, Colla-2. Its other products include Equirex, Doxypal DR-L, JP Tone Syrup, and Lycored Syrup.

MANAGEMENT

Rajpal Kochhar Chairman of the Board, Managing Director
Sachin Jain Chief Financial Officer
Pratham Rawal Compliance Officer, Company Secretary
Manish Gupta Managing Director, Additional Director

JAGSONPAL PHARMACEUTICALS SUMMARY

Jagsonpal Pharmaceuticals is trading 1.90% upper at Rs 217.15 as compared to its last closing price. Jagsonpal Pharmaceuticals has been trading in the price range of 217.95 & 212.95. Jagsonpal Pharmaceuticals has given -12.76% in this year & 4.3% in the last 5 days.

Jagsonpal Pharmaceuticals has TTM P/E ratio 26.5 as compared to the sector P/E of 24.5.

The company posted a net profit of 6.58 Crores in its last quarter.

Listed peers of Jagsonpal Pharmaceuticals include Neuland Laboratories (0.63%), Unichem Laboratories (2.32%), Jagsonpal Pharmaceuticals (1.9%) etc.

Jagsonpal Pharmaceuticals has a 67.78% promoter holding & 32.22% public holding.

FAQs about Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals is trading at 217.15 as on 19 May, 2025 10:59:30 AM. This is 1.90% upper as compared to its previous closing price of 213.1

The market capitalization of Jagsonpal Pharmaceuticals is 1439.43 Cr as on 19 May, 2025 10:59:30 AM.

The 52 wk high for Jagsonpal Pharmaceuticals is 328.02 whereas the 52 wk low is 109.42

Jagsonpal Pharmaceuticals can be analyzed on the following key metrics -

TTM P/E: 26.5
Sector P/E: 24.5
Dividend Yield: 1.17%
D/E ratio: -

Jagsonpal Pharmaceuticals reported a net profit of 55.36 Cr in 2025.

Jagsonpal Pharmaceuticals Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Jagsonpal Pharmaceuticals Share Price

Price Range

Price Range

Key Metrics

Jagsonpal Pharmaceuticals Analysis

Jagsonpal Pharmaceuticals News

Stocks to watch: Mankind, TechM, IndiGo, Adani Green, DLF, Ashok Leyland

Jagsonpal Pharmaceuticals Financials

Forecast

Forecast

Forecast

Jagsonpal Pharmaceuticals Technical

Jagsonpal Pharmaceuticals Peers

Jagsonpal Pharmaceuticals Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Jagsonpal Pharmaceuticals

MANAGEMENT

JAGSONPAL PHARMACEUTICALS SUMMARY

FAQs about Jagsonpal Pharmaceuticals

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue